Gilead Sciences Inc said on Friday additional data from a late-stage study revealed its antibacterial remdesivir significantly enhanced clinical recovery from seriously ill COVID-19 patients.

Findings from a study of its late-stage study revealed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percentage of individuals receiving standard of care, the business said.

Gilead shares were up almost 2 percent 76.14 prior to the bell.